Document Detail


[Novel anticoagulants for stroke prevention in atrial fibrillation].
MedLine Citation:
PMID:  21064013     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The most frequent cardiac arrhythmia and main cause for cardio-embolic stroke is atrial fibrillation. Prophylaxis for thrombembolic events is performed regarding individual risk of patients with either ASS or vitamin-K-antagonists. Efficacy and safety of oral anticoagulation is limited by a narrow therapeutical range as well as by inter- and intraindividual variability of INR-values due to genetic disposition, differences in alimentation, dosage errors, rare control of INR-levels and drug-interactions. New oral anticoagulants with different mechanisms of action may be a promising therapeutic option in future. This review addresses the new anticoagulants Apixaban, Rivaroxban and Dabigatranetexilat with the design and as available the results of the corresponding phase-III-trials in atrial fibrillation (ARISTOTLE, ROCKET-AF, RE-LY).
Authors:
M Baumhäkel; S H Schirmer; M Böhm
Related Documents :
15306743 - A rationale for the use of anticoagulation in heart failure management.
12953263 - Speech production after stroke: the role of the right pars opercularis.
17372173 - Prognostic significance of the centers for disease control/american heart association h...
Publication Detail:
Type:  English Abstract; Journal Article; Review     Date:  2010-11-09
Journal Detail:
Title:  Deutsche medizinische Wochenschrift (1946)     Volume:  135     ISSN:  1439-4413     ISO Abbreviation:  Dtsch. Med. Wochenschr.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-11-10     Completed Date:  2010-12-02     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  0006723     Medline TA:  Dtsch Med Wochenschr     Country:  Germany    
Other Details:
Languages:  ger     Pagination:  2304-8     Citation Subset:  IM    
Copyright Information:
© Georg Thieme Verlag KG Stuttgart · New York.
Affiliation:
Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes. magnus@baumhaekel.de
Vernacular Title:
Neue Antikoagulanzien für die Thromboembolieprophylaxe bei Vorhofflimmern.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / classification,  therapeutic use*
Antithrombins / therapeutic use
Atrial Fibrillation / complications*,  drug therapy
Azetidines / therapeutic use
Benzimidazoles / therapeutic use
Benzylamines / therapeutic use
Clinical Trials, Phase III as Topic
Factor Xa / antagonists & inhibitors
Fibrinolytic Agents / classification,  therapeutic use*
Humans
Morpholines / therapeutic use
Pyrazoles / therapeutic use
Pyridines / therapeutic use
Pyridones / therapeutic use
Stroke / prevention & control*
Thiophenes / therapeutic use
Thromboembolism / prevention & control*
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Antithrombins; 0/Azetidines; 0/Benzimidazoles; 0/Benzylamines; 0/Fibrinolytic Agents; 0/Morpholines; 0/Pyrazoles; 0/Pyridines; 0/Pyridones; 0/Thiophenes; 0/rivaroxaban; 2E18WX195X/dabigatran etexilate; 3Z9Y7UWC1J/apixaban; 49HFB70472/ximelagatran; EC 3.4.21.6/Factor Xa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  [Polycythemia].
Next Document:  [52-year-old patient with transient exanthema, fever, and arthralgias. Adult-onset Still's disease].